Volcano Reports Dismal 4Q - Analyst Blog
February 22 2013 - 5:20AM
Zacks
Volcano
Corporation (VOLC) reported earnings per share ("EPS") of
4 cents in the fourth quarter of fiscal 2012. The reported result
missed the Zacks Consensus Estimate by 5 cents as well as the
year-ago EPS of 54 cents. However, if we adjust a portion of the
company's deferred tax valuation allowance from both the periods,
Volcano would incur a loss of 5 cents per share in the reported
quarter compared with an adjusted EPS of 14 cents in the year-ago
quarter. For the full year, EPS came in at 15 cents, missing the
Zacks Consensus Estimate of 19 cents and down 78.6% year over year.
The fiscal results included benefits from the company's deferred
tax valuation allowance.
As per the company’s declaration in
the J P Morgan Healthcare conference last month, revenues for the
quarter climbed 10% year over year (up 12% at constant exchange
rate or CER) to $102.5 million, almost in line with the Zacks
Consensus Estimate. This resulted in total revenue of $381.9
million for the fiscal 2012, up 11% year over year (up 12% at CER),
in line with the Zacks Consensus Estimate and within the company’s
guided range of $380–$384 million.
Revenues in the Medical segment
increased 10% (12% increase at CER) during the fourth quarter to
$100 million with an 11% increase in disposable revenues at CER,
based on a robust 45% hike in FFR (Fractional Flow Reserve)
disposable business along with growth across all the key operating
regions. The Industrial segment recorded revenues of $2.5 million
in the fourth quarter, up 63% year over year.
Over the past few quarters, the
company has been benefiting from a growing volume of data,
depicting improved patient outcomes and economic benefits from the
use of functional percutaneous interventional (“PCI”) as well as
the use of intravascular guidance to optimize and confirm the
therapy during the procedure.
The European market recorded a
decline of 13% in intravascular ultrasound (IVUS) disposable sales,
with the U.S. growing 2% and Japan declining 4%. However, in spite
of this disappointing performance, Volcano believes that the recent
acquisitions of Sync-RX and Crux Biomedical would boost growth.
Sync-RX provides an advanced imaging technology, which will be
incorporated into a multi-modality platform, whereas Crux offers a
novel inferior vena cava (IVC) filter and related offerings. These
acquisitions remain in line with the company’s strategy to move
beyond intravascular imaging to a wide variety of diagnostic and
therapeutic solutions for both coronary and peripheral
applications.
The company is confident about the
potential of the IVUS and FM (functional measurement) markets based
on some favorable trends in the industry in the form of greater
clinical and economic pressure to prove the benefits of PCI
procedures. By the middle of the decade, the penetration rate of
integrated consoles in cath labs is expected to reach 80% or more
from the current level of just over 30%. Banking on its ability to
continuously upgrade technology and reduce cost, the company is
confident of reaping maximum advantage from this lucrative market.
Volcano expects its core IVUS and FM businesses to grow over 20%
annually coupled with additional revenues from its product
pipeline.
Volcano Corporation recorded a 56
basis points (bps) contraction in gross margin to 66.7% in the
quarter. However, with selling, general and administrative expenses
increasing 14.2% to $45.8 million and a 16.8% increase in research
and development (R&D) expenses to $14.9 million, the company
recorded a drop of 280 basis points in operating margin to 7.5%
(excluding amortization of intangibles).
Volcano exited the fiscal with
cash, cash equivalents and short-term investments of $471.5 million
compared with $219.3 million at the end of fiscal 2011. Full-year
operating cash flow came at $49.8 million compared with $43.6
million for last year.
Outlook
Volcano Corporation provided its
outlook for fiscal 2013. It expects revenues in the range of
$422.0–$428.0 million (at CER). The Zacks Consensus Estimate of
$427 million remains at the upper end of the guided range. In
addition, the company expects adjusted EPS in the range of 16–20
cents in 2013. The Zacks Consensus Estimate of 35 cents is way
above the expected range. Moreover, gross margin is expected to
remain in the range of 65%–66% and operating expenses in the band
of 61%–62% of revenues.
Recommendation
Volcano Corporation has a strong
portfolio, which should ensure growth over the long term. Pipeline
development is also progressing. Based on its direct sales program,
the company is growing rapidly in Japan to capture 50% market share
in the region. Given the termination of several distribution
agreements over the past few years, the company is now well placed
to address 100% of the business in Japan on a direct basis. Japan
continues to be an important IVUS growth opportunity for the
company, despite the high penetration level of nearly 80%.
However, capital spending by
hospitals has been affected by the weak economy. This has affected
PCI volumes in the U.S., Europe and Japan resulting in slower
growth of the IVUS disposable business in the recent past.
Moreover, unfavorable currency movement continues to be a major
headwind for the company. Volcano faces tough competition from
Boston Scientific Corporation (BSX) for the IVUS
range of products.
The stock retains a Zacks Rank #3
(Hold). Other medical device stocks worth a look are
Medical Action Industries Inc. (MDCI) and
Given Imaging Ltd. (GIVN). All these stocks carry
a Zacks Rank #1 (Strong Buy).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis Report
MEDICAL ACTION (MDCI): Free Stock Analysis Report
VOLCANO CORP (VOLC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024